Idiopathic Membranous Nephropathy Treatment Market to Witness Significant Growth with R&D in Idiopathic Membranous Nephropathy
Idiopathic membranous nephropathy a glomerular disease usually of abrupt onset and associated with the nephrotic syndrome. Membranous nephropathy occurs when the small blood vessels in the kidney (glomeruli), which filter wastes from the blood, become damaged and thickened. As a result, proteins leak from the damaged blood vessels into the urine (proteinuria). R&D in idiopathic membranous nephropathy is expected to aid in growth of the idiopathic membranous nephropathy treatment market. In July 2019, the study, ‘Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy’ stated that rituximab as effective as cyclosporine in inducing complete or partial remission of proteinuria at 12 months and was superior in maintaining proteinuria remission up to 24 months. Most leading manufactures in the idiopathic membranous nephropathy treatment market are involved in the production of medicines for treatment of idiopathic membranous nephropathy. Recent clinical trials ha...